{
  "extraction_metadata": {
    "timestamp": "2025-08-25T12:58:16.279215",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 4,
    "total_picos": 18
  },
  "picos_by_country": {
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel (only for patients with PD-L1 negative tumours)",
          "Outcomes": "Overall survival, progression-free survival, side effects, health status"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Pemetrexed (only for patients with PD-L1 negative tumours and except in cases predominantly squamous histology)",
          "Outcomes": "Overall survival, progression-free survival, side effects, health status"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Nivolumab",
          "Outcomes": "Overall survival, progression-free survival, side effects, health status"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Pembrolizumab (only for patients with PD-L1 expressing tumours (PD-L1 expr â‰¥ 1% of tumour cells))",
          "Outcomes": "Overall survival, progression-free survival, side effects, health status"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Atezolizumab",
          "Outcomes": "Overall survival, progression-free survival, side effects, health status"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumours and adenocarcinoma histology)",
          "Outcomes": "Overall survival, progression-free survival, side effects, health status"
        },
        {
          "Population": "Adults for whom docetaxel is the appropriate patient-individual therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel",
          "Outcomes": "Overall survival, morbidity, health-related quality of life, side effects"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6930
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "PICOs": [],
      "ChunksUsed": 6,
      "ContextTokens": 1644
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "patients with NDRP with a KRAS G12C mutation who have experienced disease progression after at least one line of previous use",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorasib",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), quality of life"
        },
        {
          "Population": "patients with NDRP with a KRAS G12C mutation who have experienced disease progression after at least one line of previous use",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel (DOC)",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), quality of life"
        },
        {
          "Population": "patients with NDRP with a KRAS G12C mutation who have experienced disease progression after at least one line of previous use",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nintedanib in combination with docetaxel (NIN+DOC)",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), quality of life"
        },
        {
          "Population": "patients with NDRP with a KRAS G12C mutation who have experienced disease progression after at least one line of previous use",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed (PMX)",
          "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), quality of life"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6780
    },
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, safety, quality of life"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel + nintedanib",
          "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, safety, quality of life"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, safety, quality of life"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, safety, quality of life"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, safety, quality of life"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, safety, quality of life"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "platinum doublet",
          "Outcomes": "overall survival, progression-free survival, objective response rate, duration of response, safety, quality of life"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 7430
    }
  }
}